horizon op 106 melflufen plus dexamethasone in patients

HORIZON (OP-106) An exploratory analysis of time-to-next

HORIZON (OP-106) An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex). HORIZON (OP‐106 NCT) is an ongoing pivotal single‐arm multicentre Phase II study designed to evaluate the efficacy and safety of melflufen plus dexamethasone in heavily pretreated and poor‐risk patients with RRMM refractory to pomalidomide or anti‐CD38 monoclonal antibody or both.

Melflufen plus dexamethasone in relapsed/refractory

HORIZON (OP‐106 NCT) is an ongoing pivotal single‐arm multicentre Phase II study designed to evaluate the efficacy and safety of melflufen plus dexamethasone in heavily pretreated and poor‐risk patients with RRMM refractory to pomalidomide or anti‐CD38 monoclonal antibody or both. HORIZON (OP-106) An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).

Good News on the HORIZON Melflufen Induces Response in

Melflufen was administered with dexamethasone according to the following dosing schedule melflufen 40 mg on day 1 and dexamethasone 40 mg on days 1 8 15 and 22. Patients received treatment until disease progression or unacceptable toxicity. HORIZON (OP‐106 NCT) is an ongoing pivotal single‐arm multicentre Phase II study designed to evaluate the efficacy and safety of melflufen plus dexamethasone in heavily pretreated and poor‐risk patients with RRMM refractory to pomalidomide or anti‐CD38 monoclonal antibody or both.

HORIZON (OP-106) Melflufen Plus Dexamethasone in

Larocca A et al ASH 2020 #2293 HORIZON (OP-106) Melflufen Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma—Age Subgroup Analysis of Elderly Patients Oct 01 2020 · In early phase studies (O-12-M1 and HORIZON OP-106 ) melflufen plus dexamethasone has demonstrated encouraging clinical activity and a manageable safety profile in heavily pretreated patients with relapsed/refractory multiple myeloma including those with triple-class refractory disease and extramedullary disease.

HORIZON (OP-106) Melflufen Plus Dexamethasone in Patients

HORIZON (OP-106) Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup Analysis In early phase studies (O-12-M1 and HORIZON OP-106 ) melflufen plus dexamethasone has demonstrated encouraging clinical activity and a manageable safety profile in heavily pretreated patients with relapsed/refractory multiple myeloma including those with triple-class refractory disease and extramedullary disease.

Good News on the HORIZON Melflufen Induces Response in

Melflufen was administered with dexamethasone according to the following dosing schedule melflufen 40 mg on day 1 and dexamethasone 40 mg on days 1 8 15 and 22. Patients received treatment until disease progression or unacceptable toxicity. HORIZON (OP-106) Melflufen plus dexamethasone in relapsed/refractory multiple myeloma (RRMM) refractory to pomalidomide and/or an anti-CD38 monoclonal antibodyprimary and subgroup analysis. Final Abstract Code EP945. First author Paul G Richardson.

ASH 2019Oncopeptides

Dec 07 2019 · Poster Melflufen in Amyloidosis_ASH poster_WEB_08Dec2019 . Title The Burden of Relapsed/Refractory Multiple Myeloma An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone HORIZON (OP-106) Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup Analysis

EHA 2019 Updated analysis of the HORIZON phase II trial

On Sunday 16 June at the 24 th Congress of the European Hematology Association (EHA) Paul Richardson presented Abstract S1605 showcasing updated results of the phase II HORIZON (OP-106) trial (NCT).This study investigated the efficacy and safety of melflufen and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM). 1 3214 HORIZON (OP-106) Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)—Subgroup Analysis Program Oral and Poster Abstracts

Oncopeptides Announces New Clinical and Preclinical

HORIZON (OP-106) An exploratory analysis of time to next treatment in patients with relapsed/refractory multiple myeloma who received melflufen plus dexamethasone Nov 05 2020 · In the phase 2 HORIZON study (OP-106 NCT) melflufen plus dexamethasone (dex) demonstrated encouraging efficacy and a clinically manageable safety profile in patients with heavily pretreated RRMM (Richardson et al. EHA 2020.

HORIZON (OP-106) Melflufen Plus Dexamethasone in

The safety and efficacy of melflufen plus dexamethasone were established in a phase 1/2 study in patients with RRMM who received ≥2 prior lines of therapy (Richardson et al. Blood. suppl abstr 3150). The aim of this study was to evaluate the efficacy and safety of melflufen plus dexamethasone in patients with RRMM in the pivotal Evaluate the efficacy and safety of melflufen plus dexamethasone in RRMM in the pivotal single-arm multicenter phase 2 HORIZON study (NCT). Methods Patients who had RRMM ≥2 prior lines of therapy (≥1 IMiD ≥1 proteasome inhibitor PI ) and were refractory to pomalidomide and/or an anti-CD38 mAb received melflufen plus

Melflufen plus dexamethasone in relapsed/refractory

HORIZON (OP‐106 NCT) is an ongoing pivotal single‐arm multicentre Phase II study designed to evaluate the efficacy and safety of melflufen plus dexamethasone in heavily pretreated and poor‐risk patients with RRMM refractory to pomalidomide or anti‐CD38 monoclonal antibody or both. Jun 26 2020 · Trial findings were presented in a poster titled " HORIZON (OP‑106) Melflufen Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or an Anti‑CD38 Monoclonal Antibody — Primary and Subgroup Analysis " at the 25 th European Hematology Association meeting (EHA) which took place virtually June 11–21.

Oncopeptides Reports Positive Results from HORIZON Trial

Jun 26 2020 · Trial findings were presented in a poster titled " HORIZON (OP‑106) Melflufen Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or an Anti‑CD38 Monoclonal Antibody — Primary and Subgroup Analysis " at the 25 th European Hematology Association meeting (EHA) which took place virtually June 11–21. In the phase 2 HORIZON study (OP-106 NCT) melflufen plus dexamethasone (dex) demonstrated encouraging efficacy and a clinically manageable safety profile in patients with heavily pretreated RRMM (Richardson et al. EHA 2020. Abs. EP945).

HORIZON (OP-106) Melflufen Plus Dexamethasone in Patients

HORIZON (OP-106) Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup Analysis Nov 05 2020 · Melflufen plus dexamethasone (dex) showed clinically meaningful efficacy and a manageable safety profile in patients with heavily pretreated and poor-risk RRMM in the phase 2 HORIZON study (OP-106 NCT Richardson et al. EHA 2020. Abs. EP945).

HORIZON (OP-106) Melflufen Plus Dexamethasone in

Larocca A et al ASH 2020 #2293 HORIZON (OP-106) Melflufen Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma—Age Subgroup Analysis of Elderly Patients On Sunday 16 June at the 24 th Congress of the European Hematology Association (EHA) Paul Richardson presented Abstract S1605 showcasing updated results of the phase II HORIZON (OP-106) trial (NCT).This study investigated the efficacy and safety of melflufen and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM). 1

Melflufen plus Dexamethasone in Patients with RRMM

Reference. Abstract and Poster EP945. EHA 2020. June 12 2020. HORIZON (OP-106) Melflufen plus dexamethasone in relapsed/refractory multiple myeloma (RRMM) refractory to pomalidomide and/or an anti-CD38 monoclonal antibodyprimary and subgroup analysis. Abstract and Poster EP945. EHA 2020. June 12 2020. HORIZON (OP-106) melflufen plus dexamethasone in relapsed/refractory multiple myeloma (RRMM) refractory to pomalidomide and/or an anti-CD38 monoclonal antibodyprimary and subgroup analysis.

Oncopeptides Announces that New Data for Melflufen is

Nov 04 2020 · In the pivotal phase 2 HORIZON study melflufen plus dexamethasone demonstrated encouraging efficacy and a clinically manageable safety profile In the phase 2 HORIZON study (OP-106 NCT) the activity of melflufen plus dexamethasone was demonstrated in heavily pretreated R/R MM patients refractory to pomalidomide and/or anti-CD38 monoclonal antibody (mAb) therapy with acceptable safety 2 3 .

Poster HORIZON (OP‑106) Melflufen Plus Dexamethasone

melflufen in this hard to treat patient population • The efficacy and safety of melflufen plus dex are being further evaluated in OCEAN (OP‑103) a randomized head‑to‑head superiority open‑label global phase 3 study of melflufen plus dex vs pom plus dex in patients with RRMM refractory to lenalidomide (NCT) REFERENCES 1.

Get Price

Oncopeptides Reports Positive Results from HORIZON Trial

Jun 26 2020 · Trial findings were presented in a poster titled " HORIZON (OP‑106) Melflufen Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or an Anti‑CD38 Monoclonal Antibody — Primary and Subgroup Analysis " at the 25 th European Hematology Association meeting (EHA) which took place virtually June 11–21. HORIZON (OP-106) Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis. Richardson PG et